JP-2022530636-A5 -

Dates

Publication Date

20230512

Application Date

20200428

Description

Preferred embodiments of the present invention are shown and described herein, but it will be apparent to those skilled in the art that such embodiments are provided merely as examples. Those skilled in the art will be able to conceive of numerous variations, alterations, and substitutions without departing from the present invention. It should be understood that various alternatives to the embodiments of the present invention described herein can be used in carrying out the present invention. The following claims define the scope of the present invention, and the methods and structures within these claims, as well as their equivalents, are intended to be covered thereby. In certain embodiments, for example, the following are provided: (Item 1) A method for detecting the presence or absence of endometriosis in female subjects, (a) A step of detecting the expression profile of a panel of endometriosis-related miRNAs in a bodily fluid sample from the female subject, wherein the panel of endometriosis-related miRNAs includes miR-342 or miR451a, (b) A step of applying a machine learning algorithm to the expression profiles of the panel of miRNAs associated with endometriosis, wherein the machine learning algorithm has an importance scale assigned to the characteristics of the miRNAs, i. An importance scale is assigned to miR-342, and the importance scale assigned to miR-342 is greater than the importance scale assigned to at least one miRNA selected from the group consisting of miR-150, miR-3613, miR-451a, let-7b, and miR-125b, or ii. A step in which an importance scale is assigned to miR-451a, and the importance scale assigned to miR-451a is greater than the importance scale assigned to at least one miRNA selected from the group consisting of miR-3613, miR-125b, and let-7b. (c) The step of detecting the presence or absence of endometriosis in the female subject using the machine learning algorithm described above. Methods that include... (Item 2) The method according to item 1, wherein the female subject has symptoms of endometriosis. (Item 3) The method according to item 1, wherein the female subject has symptoms of endometriosis selected from the group consisting of abdominal pain, digestive problems, excessive bleeding, infertility, and menstrual irregularities. (Item 4) The method according to any one of the preceding items, wherein the subject has not been previously diagnosed with endometriosis. (Item 5) The method according to any one of the preceding items, wherein the subject has been previously diagnosed with endometriosis, and the method confirms the presence of endometriosis in the female subject. (Item 6) The method according to any one of the preceding items, further comprising the step of diagnosing endometriosis in the female subject if the presence of endometriosis is detected. (Item 7) The method according to any one of the preceding items, further comprising the step of predicting or monitoring endometriosis in the female subject if the presence of endometriosis is detected. (Item 8) The method according to any one of the preceding items, further comprising the step of treating the female subject for endometriosis if the presence of endometriosis is detected. (Item 9) The method according to any one of the preceding items, further comprising the step of determining that the female subject is in a state that is not endometriosis if the absence of endometriosis is detected. (Item 10) The method according to any one of the preceding items, further comprising the step of treating the female subject for the non-endometriotic condition if the absence of endometriosis is detected. (Item 11) The method for any one of the preceding items, wherein the importance scale assigned to miR-342 is greater than the importance scale assigned to at least one miRNA selected from the group consisting of miR-150, miR-3613, miR-451a, let-7b, and miR-125b. (Item 12) The method according to item 11, wherein the importance scale assigned to miR-342 is smaller than the importance scale assigned to at least one other miRNA. (Item 13) The method for any one of the preceding items, wherein the importance scale assigned to miR-342 is greater than the importance scale assigned to at least two miRNAs selected from the group consisting of miR-150, miR-3613, miR-451a, let-7b, or miR-125b. (Item 14) The method for any one of the preceding items, wherein the importance scale assigned to miR-342 is greater than the importance scale assigned to at least three miRNAs selected from the group consisting of miR-150, miR-3613, miR-451a, let-7b, or miR-125b. (Item 15) The method for any one of the preceding items, wherein the importance scale assigned to miR-342 is greater than the importance scale assigned to at least four miRNAs selected from the group consisting of miR-150, miR-3613, miR-451a, let-7b, and miR-125b. (Item 16) The method according to any one of the preceding items, wherein the importance scale assigned to miR-342 is gr